Tools commonly used in the Chelation Therapy industry for day-to-day tasks and operations.

• EDTA (ethylenediaminetetraacetic acid)
• DMPS (2,3-dimercapto-1-propanesulfonic acid)
• DMSA (dimercaptosuccinic acid)
• Vitamin C
• Magnesium
• Zinc
• Selenium
• Glutathione
• Alpha-lipoic acid
• N-acetylcysteine

Common products and services typical of NAICS Code 621340-10, illustrating the main business activities and contributions to the market.

• Heavy metal toxicity
• Atherosclerosis
• Coronary artery disease
• Autism
• Alzheimer's disease
• Parkinson's disease
• Multiple sclerosis
• Chronic fatigue syndrome
• Fibromyalgia
• Peripheral artery disease

The specific certifications, permits, licenses, and regulatory compliance requirements within the United States for this industry.

• Certified Clinical Chelationist (CCC): This certification is offered by the American College for Advancement in Medicine (ACAM) and is designed for physicians who have completed a training program in chelation therapy. The certification requires passing an exam and completing continuing education credits.
• Board Certification In Integrative Medicine: This certification is offered by the American Board of Integrative Medicine (ABOIM) and is designed for physicians who have completed a residency in integrative medicine. Chelation therapy is one of the treatments covered in the certification.
• Certified Nutrition Specialist (CNS): This certification is offered by the Board for Certification of Nutrition Specialists (BCNS) and is designed for professionals who have completed a master's or doctoral degree in nutrition and have at least 1,000 hours of supervised experience. Chelation therapy is one of the treatments covered in the certification.
• Certified Environmental Consultant (CEC): This certification is offered by the National Registry of Environmental Professionals (NREP) and is designed for professionals who have completed a degree in environmental science or a related field and have at least 5 years of experience in environmental consulting. Chelation therapy is one of the treatments covered in the certification.
• Certified Clinical Metal Toxicologist (CCMT): This certification is offered by the International Board of Clinical Metal Toxicology (IBCMT) and is designed for professionals who have completed a training program in clinical metal toxicology. Chelation therapy is one of the treatments covered in the certification.

A concise historical narrative of NAICS Code 621340-10 covering global milestones and recent developments within the United States.

• Chelation therapy has been used for over 50 years to treat heavy metal poisoning, such as lead and mercury. In the 1950s, it was discovered that chelation therapy could also be used to treat atherosclerosis, a condition where plaque builds up in the arteries. Since then, chelation therapy has been used as an alternative treatment for heart disease, autism, and other conditions. In recent years, chelation therapy has gained popularity in the United States as a complementary and alternative medicine (CAM) treatment for heart disease. However, the effectiveness of chelation therapy for heart disease is still a topic of debate in the medical community. Recent history of chelation therapy in the United States has been marked by controversy. In 2012, the National Institutes of Health (NIH) conducted a clinical trial to determine the effectiveness of chelation therapy for heart disease. The trial, known as the Trial to Assess Chelation Therapy (TACT), found that chelation therapy was effective in reducing the risk of heart attacks, strokes, and other cardiovascular events in patients with a history of heart disease. However, the study has been criticized for its small sample size and lack of a placebo group. Despite the controversy, chelation therapy continues to be used as a CAM treatment for heart disease in the United States.

The anticipated future trajectory of the NAICS 621340-10 industry in the USA, offering insights into potential trends, innovations, and challenges expected to shape its landscape.

• Growth Prediction: Stable

  Chelation Therapy is expected to grow in the coming years due to the increasing prevalence of cardiovascular diseases and the aging population in the USA. The industry is also expected to benefit from the growing demand for alternative therapies and the increasing awareness of the benefits of chelation therapy. However, the industry may face challenges due to the lack of scientific evidence supporting the effectiveness of chelation therapy and the potential risks associated with the treatment. Overall, the industry is expected to experience moderate growth in the coming years.

Recent groundbreaking advancements and milestones in the Chelation Therapy industry, reflecting notable innovations that have reshaped its landscape.

• Development Of New Chelating Agents: Researchers are developing new chelating agents that are more effective and have fewer side effects than traditional agents.
• Combination Therapy: Some practitioners are combining chelation therapy with other therapies, such as nutritional supplements and exercise, to enhance the effectiveness of the treatment.
• Oral Chelation Therapy: Some companies are developing oral chelation therapy products that can be taken at home, which may increase the accessibility of the treatment.
• Use Of Chelation Therapy for Other Conditions: Some practitioners are using chelation therapy to treat other conditions, such as autism and Alzheimer's disease, which may expand the market for the treatment.
• Increased Regulation: The FDA has increased its regulation of chelation therapy in recent years, which may improve the safety and effectiveness of the treatment.